Kamada (Kamada) Asset Impairment Charge : $0.0 Mil (TTM As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Kamada Asset Impairment Charge?

Kamada's Asset Impairment Charge for the three months ended in Dec. 2023 was $0.0 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Dec. 2023 was $0.0 Mil.

Kamada Asset Impairment Charge Historical Data

The historical data trend for Kamada's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kamada Asset Impairment Charge Chart

Kamada Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Asset Impairment Charge

Get a 7-Day Free Trial

Kamada Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Asset Impairment Charge	Get a 7-Day Free Trial															-	-	-	-	-

Kamada Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.0 Mil.

Kamada Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Kamada's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

Kamada (Kamada) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kamada Ltd (NAS:KMDA) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

KMDA:Israel

Address

2 Holzman Street, P.O. Box 4081, Science Park, Rehovot, ISR, 7670402

Website

https://www.kamada.com

Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, Proprietary Products segment and Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.